ReviewMolecular biology reports2022
COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression.
Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Transcriptomic and proteomic profiling of pulmonary mucormycosis reveals a failed activation of host immune response.Frontiers in immunology · 2026Article
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview.Infectious disorders drug targets · 2025Review
- Precision Detection of Fungal Co-Infections for Enhanced COVID-19 Treatment Strategies Using FESEM Imaging.Indian journal of microbiology · 2024Article
- Factors Impacting Outcome and Prognosis of Invasive Fungal Sinusitis: How Vital is Iron Metabolism?Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Investigating the Hepcidin Gene Polymorphisms in COVID-19-Associated Mucormycosis Susceptibility: A Clinical-Laboratory Study.Iranian journal of medical sciences · 2024Article
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Endocarditis caused by Aspergillus fumigatus in a patient 9 months after COVID-19 infection recovery: a case report and review of the literature.Journal of medical case reports · 2023Review
- COVID-19 in Bangladesh: Wave-centric assessments and mitigation measures for future pandemics.Heliyon · 2023Review
- COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023Review
- Classical Presentation of Disseminated Blastomycosis in a 44-Year-Old Healthy Man 3 Months After Diagnosis of COVID-19.The American journal of case reports · 2023Article
- Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.Environmental science and pollution research international · 2023Review
- Invasive fungal disease in COVID-19 patients: a single-center prospective observational study.Frontiers in medicine · 2023Article
- Mucormycosis in pre-COVID-19 and COVID-19 era: A study of prevalence, risk factors and clinical features.Laryngoscope investigative otolaryngology · 2022Article
- Review
- COVID-19-Associated Candidiasis: Possible Patho-Mechanism, Predisposing Factors, and Prevention Strategies.Current microbiology · 2022Review
- Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and Why.Current fungal infection reports · 2022Review
- Immunoinformatic Design of a Multivalent Peptide Vaccine Against Mucormycosis: Targeting FTR1 Protein of Major Causative Fungi.Frontiers in immunology · 2022Article
- Vaccine development for pathogenic fungi: current status and future directions.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19-associated-mucormycosis, commonly referred to as the "Black Fungus," is a rare secondary fungal infection in COVID-19 patients prompted by a group of mucor molds. Association of this rare fungal infection with SARS-CoV-2 infection has been declared as an endemic in India, with minor cases in several other countries around the globe. Although the fungal infection is not contagious like the viral infection, the causative fungal agent is omnipresent. Infection displays an overall mortality rate of around 50%, with many other secondary side effects posing a potential threat in exacerbating COVID-19 mortality rates. In this review, we have accessed the role of free iron availability in COVID-19 patients that might correlate to the pathogenesis of the causative fungal agent. Besides, we have analyzed the negative consequences of using immunosuppressive drugs in encouraging this opportunistic fungal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.